Many clinical trials for ALS treatments currently suffer from an inability to measure therapeutic efficacy at a mechanistic level37, so TDP-43-dependent cryptic peptide biomarkers could be used in the future to better interpret results of clinical trials and improve drug design. Here, TARDBP is linked to amyotrophic lateral sclerosis.